Business, energy, technology, markets and global industry news from Business News Today

KRAS

PharmaDeviceNews KRAS
Representative image: A clinician reviews pancreatic cancer imaging and oncology trial data as Phanes Therapeutics’ spevatamig Phase 2 results highlight the growing role of bispecific antibody research in first-line metastatic pancreatic ductal adenocarcinoma treatment.
Pharma & Biotech

Alterome Therapeutics schedules first Phase 1 clinical data presentation for pan-KRAS inhibitor ALTA3263

Alterome Therapeutics will reveal first ALTA3263 Phase 1 data in November, testing the safety and early activity of its oral pan-KRAS inhibitor.

Read More
Johnson & Johnson’s $1 billion Firefly Bio acquisition adds the preclinical Firelink degrader antibody conjugate platform to its oncology pipeline, strengthening its research into KRAS-driven cancers and other difficult-to-treat solid tumors. Representative image.
Pharma & Biotech

Johnson & Johnson just spent $1bn on a preclinical cancer platform: What must Firefly Bio prove next?

Johnson & Johnson closes its $1 billion Firefly Bio deal, adding a preclinical degrader antibody conjugate platform for KRAS-driven cancers.

Read More
Confluence Genetics’ Cas-CLEAR CRISPR platform is designed to use cancer-linked RNA mutations as triggers for selective tumor cell destruction, opening a potential new precision oncology pathway. Representative image.
Pharma & Biotech

Could Confluence Genetics’ Cas-CLEAR platform open a new path for liver cancer therapy?

Confluence Genetics launches Cas-CLEAR, a Cas12a2 CRISPR platform designed to kill mutation-bearing cancer cells. Explore the evidence and risks.

Read More
Pharma & Biotech

Ensem Therapeutics puts pan-KRAS and WRN into focus as AACR 2026 sharpens its precision oncology pitch

Read how Ensem Therapeutics is positioning ETX-929 and ETX-880 in the KRAS and MSI-H oncology races at AACR 2026.

Read More
Pharma & Biotech

PAQ Therapeutics initiates Phase 1 for PT0511 pan-KRAS degrader, raises $77m in Series B

PAQ Therapeutics begins Phase 1 trial for PT0511 pan-KRAS degrader and raises $77M. Find out what this means for the future of KRAS-targeted cancer therapy.

Read More